Prognostic value of the systemic inflammation response index (SIRI) in glioma: A meta-analysis.
Lixia Guo, Xudong Cao, Lijun Yang et al.
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis assessed whether the systemic inflammation response index (SIRI) predicts outcomes in patients with glioma. It pooled evidence from eight retrospective cohort studies involving 1,778 patients. Higher SIRI was associated with poorer overall survival (pooled HR = 1.79, 95% CI: 1.34-2.38, P < 0.0001) and progression-free survival (pooled HR = 1.46, 95% CI: 1.18-1.81, P = 0.0005). The association with overall survival was not significant in the European subgroup, and publication bias was detected for the overall-survival analysis.
Key findings
- Higher SIRI was associated with poorer overall survival (pooled HR = 1.79, 95% CI: 1.34-2.38, P < 0.0001).
- Higher SIRI was associated with poorer progression-free survival (pooled HR = 1.46, 95% CI: 1.18-1.81, P = 0.0005).
- The overall-survival association was not significant in the European subgroup.
- Egger's test indicated publication bias in the overall-survival analysis (P = 0.0001), but not in the progression-free-survival analysis.
Why it matters
SIRI may provide prognostic information in glioma, with higher values associated with worse survival outcomes across the pooled studies. However, the subgroup inconsistency and evidence of publication bias for overall survival temper confidence in its generalizability. The findings support further evaluation of SIRI, including validation across diverse populations and use of standardized cut-off values.
What to keep in mind
The evidence came from retrospective cohorts, and the overall-survival analysis showed publication bias. The association was not significant in the European subgroup; standardized SIRI cut-off values require further validation.